<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Ferredoxin 1 is essential for embryonic development and lipid homeostasis</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2024-01-22">22 January 2024</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Shakur</forename><surname>Mohibi</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Schools of Veterinary Medicine and Medicine</orgName>
								<orgName type="laboratory">Comparative Oncology Laboratory</orgName>
								<orgName type="institution">University of California</orgName>
								<address>
									<settlement>Davis</settlement>
									<region>Davis</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yanhong</forename><surname>Zhang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Schools of Veterinary Medicine and Medicine</orgName>
								<orgName type="laboratory">Comparative Oncology Laboratory</orgName>
								<orgName type="institution">University of California</orgName>
								<address>
									<settlement>Davis</settlement>
									<region>Davis</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Vivian</forename><surname>Perng</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Schools of Veterinary Medicine and Medicine</orgName>
								<orgName type="laboratory">Comparative Oncology Laboratory</orgName>
								<orgName type="institution">University of California</orgName>
								<address>
									<settlement>Davis</settlement>
									<region>Davis</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mingyi</forename><surname>Chen</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution">University of Texas Southwestern Medical Center</orgName>
								<address>
									<settlement>Dallas</settlement>
									<region>Dallas</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jin</forename><surname>Zhang</surname></persName>
							<email>jinzhang@ucdavis.edu</email>
							<affiliation key="aff0">
								<orgName type="department">Schools of Veterinary Medicine and Medicine</orgName>
								<orgName type="laboratory">Comparative Oncology Laboratory</orgName>
								<orgName type="institution">University of California</orgName>
								<address>
									<settlement>Davis</settlement>
									<region>Davis</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Xinbin</forename><surname>Chen</surname></persName>
							<email>xbchen@ucdavis.edu</email>
							<affiliation key="aff0">
								<orgName type="department">Schools of Veterinary Medicine and Medicine</orgName>
								<orgName type="laboratory">Comparative Oncology Laboratory</orgName>
								<orgName type="institution">University of California</orgName>
								<address>
									<settlement>Davis</settlement>
									<region>Davis</region>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><surname>Funder</surname></persName>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department">Wake Forest Baptist Medical Center</orgName>
								<address>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">http://orcid</orgName>
								<orgName type="department" key="dep2">http://orcid</orgName>
								<orgName type="institution">Shakur Mohibi http://orcid</orgName>
								<address>
									<postCode>0000-0001-5539-0841, 0000-0001-6754-0480, 0000-0002-6835-920X</postCode>
									<settlement>Mingyi Chen, Jin Zhang</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="institution">Xinbin Chen http://orcid</orgName>
								<address>
									<postCode>0000-0002-4582-6506</postCode>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Ferredoxin 1 is essential for embryonic development and lipid homeostasis</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2024-01-22">22 January 2024</date>
						</imprint>
					</monogr>
					<idno type="MD5">923F007ED0E916EA33765F51F97AB15E</idno>
					<idno type="DOI">10.7554/eLife.91656</idno>
					<note type="submission">Received: 06 August 2023 Preprinted: 24 August 2023 Accepted: 19 January 2024</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.0" ident="GROBID" when="2024-05-25T07:17+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Author contributions Shakur Mohibi, Data curation, Investigation, Writing -original draft, Writing -review and editing</term>
					<term>Yanhong Zhang, Conceptualization, Data curation, Investigation, Methodology</term>
					<term>Vivian Perng, Data curation</term>
					<term>Mingyi Chen, Formal analysis</term>
					<term>Jin Zhang, Resources, Data curation, Supervision, Methodology, Writing -review and editing</term>
					<term>Xinbin Chen, Conceptualization, Resources, Supervision, Funding acquisition, Methodology, Writing -review and editing</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Mammalian ferredoxin 1 and 2 (FDX1/2) belong to an evolutionary conserved family of iron-sulfur cluster containing proteins and act as electron shutters between ferredoxin reductase (FDXR) and numerous proteins involved in critical biological pathways. FDX1 is involved in biogenesis of steroids and bile acids, Vitamin A/D metabolism, and lipoylation of tricarboxylic acid (TCA) cycle enzymes. FDX1 has been extensively characterized biochemically but its role in physiology and lipid metabolism has not been explored. In this study, we generated Fdx1-deficient mice and showed that knockout of both alleles of the Fdx1 gene led to embryonic lethality. We also showed that like Fdxr +/-+/-, Fdx1 +/-+/-had a shorter life span and were prone to steatohepatitis. However, unlike Fdxr +/-+/-, Fdx1 +/-+/-were not prone to spontaneous tumors. Additionally, we showed that FDX1 deficiency led to lipid droplet accumulation possibly via the ABCA1-SREBP1/2 pathway. Specifically, untargeted lipidomic analysis showed that FDX1 deficiency led to alterations in several classes of lipids, including cholesterol, triacylglycerides, acylcarnitines, ceramides, phospholipids and lysophospholipids. Taken together, our data indicate that FDX1 is essential for mammalian embryonic development and lipid homeostasis at both cellular and organismal levels.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Editor's evaluation</head><p>The findings provided by Mohibi et al. are important to the field of lipid metabolism and cancer and provide insight for an in vivo role of FDX1. The evidence is solid, utilizing multiple modalities and both in vitro and in vivo lines of investigation.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>Ferredoxin (FDX) proteins are a family of redox proteins present in all branches of life <ref type="bibr" target="#b25">(Schulz et al., 2023)</ref>. They contain iron-sulfur (Fe-S) clusters that aid in their function of transferring electrons from NADPH via ferredoxin reductase (FDXR) to systems involved in various biological processes including iron sulfur (Fe-S) cluster synthesis, steroidogenesis, bile acid production and vitamin metabolism. Mammalian cells contain two ferredoxins, FDX1 and FDX2, both of which are localized to mitochondria <ref type="bibr" target="#b28">(Sheftel et al., 2010)</ref>. Although they have high homology in primary and three-dimensional structures, they differ significantly in their substrate identity and function <ref type="bibr" target="#b25">(Schulz et al., 2023)</ref>. FDX2 is critical in the formation of Fe-S clusters in mitochondria by donating electrons to iron sulfur cluster assembly complex <ref type="bibr" target="#b25">(Schulz et al., 2023)</ref>. FDX1, on the other hand, donates its electrons to various cytochrome p450 systems present in mitochondria and is involved in production of steroid hormones from cholesterol (steroidogenesis), bile acid production, addition of heme Î± to Cytochrome c as well as Vitamin A/D metabolism <ref type="bibr" target="#b25">(Schulz et al., 2023)</ref>. Recently, FDX1 has been shown to regulate the process of lipoylation of tricarboxylic acid (TCA) cycle enzymes, especially pyruvate dehydrogenase (PDH) and a-ketoglutarate dehydrogenase <ref type="bibr" target="#b25">(Schulz et al., 2023 ;</ref><ref type="bibr" target="#b34">Tsvetkov et al., 2022)</ref>. Lipoylation is essential for the function of these enzymes. Moreover, FDX1 has emerged as the central player in the regulation of a new form of cell death, called cuproptosis <ref type="bibr" target="#b34">(Tsvetkov et al., 2022;</ref><ref type="bibr" target="#b33">Tsvetkov et al., 2019)</ref>.</p><p>Lipids consist of a myriad group of biomolecules essential for various cellular processes, including membrane formation, energy storage and cellular signaling pathways <ref type="bibr" target="#b32">(Snaebjornsson et al., 2020)</ref>. Some vital lipids, such as triaclyglycerides (TAGs), cholesterol, cardiolipins (CLs) and phospholipids, are essential for cell survival. Due to the essential role of lipids in maintaining normal physiology, aberrant lipid homeostasis has been involved in various disease pathologies, including cancer, neurodegeneration, and cardiovascular diseases <ref type="bibr" target="#b0">(Broadfield et al., 2021;</ref><ref type="bibr" target="#b9">Hoy et al., 2021;</ref><ref type="bibr" target="#b32">Snaebjornsson et al., 2020)</ref>. Altered lipid metabolism is also linked with systemic inflammation and non-alcoholic steatohepatitis (NASH) <ref type="bibr" target="#b2">(Carotti et al., 2020;</ref><ref type="bibr" target="#b9">Hoy et al., 2021;</ref><ref type="bibr" target="#b20">Pei et al., 2020;</ref><ref type="bibr" target="#b31">Singla et al., 2010)</ref>.</p><p>SREBP1/2 are considered master regulators of lipid metabolism and often associated with altered lipid homeostasis <ref type="bibr" target="#b19">(Osborne and Espenshade, 2009;</ref><ref type="bibr" target="#b26">Shao and Espenshade, 2012)</ref>. In physiological conditions, when intracellular cholesterol levels are depleted, SREBP1/2 are activated through the release of their N-terminal domains by proteolytic cleavage. The N-terminal domains are then translocated to nucleus where a set of genes involved in lipid metabolism are induced by SREBP1/2 <ref type="bibr" target="#b19">(Osborne and Espenshade, 2009;</ref><ref type="bibr" target="#b26">Shao and Espenshade, 2012)</ref>. However, in diseased conditions, SREBP1/2 are constitutively activated via various mechanisms, resulting in abnormal lipid production and accumulation <ref type="bibr" target="#b19">(Osborne and Espenshade, 2009;</ref><ref type="bibr" target="#b26">Shao and Espenshade, 2012)</ref>. SREBP1 is expressed as two isoforms, SREBP 1 a and 1 c, both of which are transcribed from the SREBF1 gene but through two separate promoters. SREBP-2 is encoded by the SREBF2 gene. SREBP-1c preferentially regulates genes for synthesis of fatty acids (FAs) and TAGs whereas SREBP-2 preferentially regulates genes for cholesterol synthetic pathway, including the mevalonate pathway <ref type="bibr" target="#b1">(Brown and Goldstein, 1997)</ref>. SREBP-1a has overlapping functions with both SREBP-1c and SREBP-2.</p><p>FDXR transfers electrons from NADPH to FDX1, which then delivers the electrons to either COX15, lipoyl synthase or seven different mitochondrial cytochromes, thus supporting the biosynthesis of heme Î±, lipoic acid, steroid hormones, bile acid, and Vitamin A/D metabolism <ref type="bibr" target="#b25">(Schulz et al., 2023)</ref>. We previously showed an essential role of FDXR in mammalian embryonic development and lipid metabolism <ref type="bibr" target="#b39">(Zhang et al., 2022;</ref><ref type="bibr" target="#b38">Zhang et al., 2017)</ref>. As FDX1 is a substrate of FDXR in regulating steroidogenesis, we asked whether FDX1 is necessary for mammalian embryonic development and lipid metabolism. We showed that mice homozygous for Fdx1 deletion are embryonically lethal at embryonic day 10.5 (E10.5). We also showed that Fdx1 +/-+/-have a short life span and are prone to steatohepatitis, but not to spontaneous tumors. Like FDXR, FDX1 was found to regulate lipid metabolism due to increased activation of the SREBP1/2 pathways. Moreover, untargeted lipidomic analysis showed that FDX1 loss leads to alterations in several classes of lipids.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p>Fdx1 -/-embryos die between E10.5 and E13.5</p><p>Although FDX1 has been extensively studied biochemically, its role in development and physiology has been unexplored. To determine physiological function of FDX1, we generated Fdx1 heterozygous mice using the knock-out first approach (Figure <ref type="figure" target="#fig_8">1A</ref> and<ref type="figure">B</ref>). The Fdx1 +/-+/-developed normally and were fertile. However, inter-breeding of Fdx1 +/-+/-to obtain Fdx1 -/-mice was unsuccessful. Out of the 67 pups obtained from the Fdx1 +/-+/-inter-breeding, none were of the Fdx1 -/-genotype (Figure <ref type="figure" target="#fig_8">1C</ref>), suggesting complete loss of Fdx1 leads to embryonic lethality. To determine at what developmental stage the embryonic lethality occurs, we isolated embryos following timed pregnancies. We did not find any Fdx1 -/-embryos at embryonic day 13.5 (E13.5) but found one at E10.5 (Figure <ref type="figure" target="#fig_8">1C</ref>), suggesting Fdx1-KO is lethal for embryos between E10.5-E13.5. Although, the size of WT and Fdx1 +/-+/-at E10.5 was comparable, Fdx1 -/-embryos were small and abnormal (Figure <ref type="figure" target="#fig_8">1D</ref> and<ref type="figure">E</ref>). Interestingly, this embryonic lethality is commensurate with that observed with the embryonic lethality of Fdxr-KO at E8.5 <ref type="bibr" target="#b38">(Zhang et al., 2017)</ref>. These results suggest that Fdx1 and Fdxr regulate similar processes required for mammalian embryonic development and survival.</p><p>Mice deficient in Fdx1 have shorter lifespan and are prone to steatohepatitis/steatosis Although Fdx1 -/-mice were embryonically lethal, Fdx1 +/-+/-were viable. Thus, to study the effect of Fdx1 loss on the long-term survival as well as predisposition to tumors and other abnormalities, we generated a cohort of Fdx1 +/-+/-. Since Fdxr catalyzes the transfer of an electron from NADPH to Fdx1, we compared the phenotypes between Fdx1 +/-+/-and Fdxr +/-+/-from our previous studies The online version of this article includes the following source data for figure <ref type="figure" target="#fig_8">1:</ref> Source data 1. Unedited DNA gel images for Figure <ref type="figure" target="#fig_8">1B</ref> and<ref type="figure">E</ref>. <ref type="bibr" target="#b39">(Zhang et al., 2022;</ref><ref type="bibr" target="#b38">Zhang et al., 2017)</ref>. To minimize the number of animals used, the data for the WT mice were adapted from two previous studies <ref type="bibr" target="#b37">(Yang et al., 2017;</ref><ref type="bibr" target="#b38">Zhang et al., 2017)</ref>, as all the mice were derived from the same C57BL/6 background and maintained in the same facility. Moreover, to avoid any influences from sex differences, all the mice cohorts were kept at close to equal ratio of male:female mice.</p><p>Previously, we found that Fdxr +/-+/-had a short life span compared to WT mice <ref type="bibr" target="#b39">(Zhang et al., 2022;</ref><ref type="bibr" target="#b38">Zhang et al., 2017)</ref>. Here, we found that the median lifespan for Fdx1 +/-+/-(73 weeks) was significantly shorter than that for WT mice (117weeks) and even shorter than that for Fdxr +/-+/-(102weeks) (Figure <ref type="figure" target="#fig_2">2A</ref> and Figure <ref type="figure" target="#fig_1">2</ref>-source data 3). To examine if the Fdx1 +/-+/-were tumor-prone, we performed histological analysis. Fdxr +/-(26 out of 29) mice were tumor-prone as compared to WT mice (11 out of 51) (p&lt;0.00001 by Fisher's exact test). However, the overall incidence of spontaneous tumors was not statistically significant between Fdx1 +/-+/-(11 out of 26) and WT mice (11 out of 51) (p=0.0673 by Fisher's exact test) (Figure <ref type="figure" target="#fig_2">2B</ref>, Figure <ref type="figure" target="#fig_1">2</ref>-source data 3). Nevertheless, like Fdxr +/-+/-, Fdx1 +/-+/-showed significantly higher incidences of adenocarcinomas and sarcomas as compared to WT mice (Figure <ref type="figure" target="#fig_2">2B-D</ref>). Out of the three Fdx1+/-mice that developed adenocarcinomas, two had lung adenocarcinomas and one had adenocarcinoma associated with the gastrointestinal tract (Figure <ref type="figure" target="#fig_2">2D</ref>, Figure <ref type="figure" target="#fig_1">2</ref>-source data 3C).</p><p>Previously, we showed that mice deficient in Fdxr were prone to liver steatosis and inflammation (Figure <ref type="figure" target="#fig_2">2E</ref>, Figure <ref type="figure" target="#fig_1">2</ref>-source data 3A,B; <ref type="bibr" target="#b39">Zhang et al., 2022;</ref><ref type="bibr" target="#b38">Zhang et al., 2017)</ref>. Since Fdxr and Fdx1 are necessary for steroidogenesis/lipid metabolism, we next examined whether Fdx1 +/-mice are susceptible to liver abnormalities. Indeed, we found that like Fdxr +/-+/-, Fdx1 +/-+/-were highly prone to liver steatosis/steatohepatitis (Figure <ref type="figure" target="#fig_2">2E</ref>-F, Figure <ref type="figure" target="#fig_1">2</ref>-source data 3C). As steatohepatitis often leads to liver cirrhosis and eventually liver failure <ref type="bibr" target="#b23">(Sanches et al., 2015)</ref>, we conclude that the high incidence of steatosis/steatohepatitis are likely responsible for the shorter lifespan observed in Fdx1 +/-+/-. Of note, we did not observe any variations in phenotypes based on any sex differences in our studies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Lack of FDX1 leads to altered lipid metabolism possibly via the ABCA1-SREBP1/2 pathway</head><p>We previously showed that FDXR regulates lipid metabolism via SREBP1/2 pathways <ref type="bibr" target="#b39">(Zhang et al., 2022)</ref>. Given that FDX1 is a substrate of FDXR during steroidogenesis, FDX1 might be involved in lipid metabolism via the same pathway. To test this, we generated Fdx1 +/-mouse embryo fibroblasts (+/-). As Fdx1 +/-+/-are lethal at E10.5, we were only able to obtain Fdx1 +/-+/-. As expected, the levels of Fdx1 protein in Fdx1 +/-+/-were approximately half of that in WT MEFs (Figure <ref type="figure" target="#fig_3">3A</ref>). To examine whether loss of FDX1 alters lipid metabolism, Nile Red (9-diethylamino-5H-benzo[a]phenoxazine-5-one) staining, which stains lipid droplets, was performed on these cells. We found intense Nile red staining in the cytoplasm of Fdx1 +/-+/-, suggesting accumulation of lipid droplets in Fdx1-deficient MEFs as compared to WT MEFs (Figure <ref type="figure" target="#fig_3">3B</ref>).</p><p>To confirm the role of Fdx1 in lipid metabolism in other murine cells, we used CRISPR-Cas9 to knock-out Fdx1 in mouse FL83B hepatocytes and SCp2 mammary epithelial cells. Unfortunately, we were not able to obtain any Fdx1-KO clones in both cell lines, indicating a requirement of Fdx1 for cell survival (Figure <ref type="figure" target="#fig_3">3C</ref> and<ref type="figure">G</ref>). Interestingly, along with the expected decrease in Fdx1 protein levels, we observed lower levels of Fdxr protein in Fdx1 +/-+/-as compared to isogenic control cells, suggesting that Fdx1 regulates Fdxr expression (Figure <ref type="figure" target="#fig_3">3G</ref> and<ref type="figure">H</ref>). Next, we performed Nile red staining to examine lipid droplet accumulation in these cells. We found that loss of Fdx1 led to increase in the accumulation of lipid droplets in the cytoplasm of FL83B and SCp2 cells (Figure <ref type="figure" target="#fig_3">3D</ref> and<ref type="figure">I</ref>), consistent with the observation in MEFs that loss of Fdx1 leads to aberrant lipid metabolism.</p><p>To investigate whether Fdx1 modulates lipid metabolism via the ABCA1-SREBP1/2 pathway, we cultured FL83B cells in serum-free medium, which mimics depletion of cholesterol response. First, we examined whether Fdx1 deficiency has an effect on the level of ABCA1, a cholesterol efflux pump, which is known to be regulated upon Fdxr deficiency <ref type="bibr" target="#b36">(Yamauchi et al., 2015)</ref>. We found that Fdx1 deficiency led to decreased expression of ABCA1 protein (Figure <ref type="figure" target="#fig_3">3E</ref> and<ref type="figure">F</ref>). Moreover, the mature nuclear form of SREBP2 protein, which is known to be increased once ABCA1 expression is decreased <ref type="bibr" target="#b18">(Moon et al., 2019)</ref>, was increased upon Fdx1 deficiency (Figure <ref type="figure" target="#fig_3">3E</ref> and<ref type="figure">F</ref>). Furthermore, we examined if Fdx1 deficiency affects the maturation of SREBP1, which is mainly involved in the fatty acid  and triacylglyceride (TAG) synthesis <ref type="bibr" target="#b30">(Shimano et al., 1997;</ref><ref type="bibr" target="#b29">Shimano et al., 1996)</ref>. We found that the mature form of SREBP1 was only slightly increased in Fdx1-deficient cells (Figure <ref type="figure" target="#fig_3">3E</ref> and<ref type="figure">F</ref>). As the maturation of SREBP2 was very robust in Fdx1-deficient cells, we further tested the induction of mevalonate decarboxylase (MVD), an SREBP2 target involved in ATP-dependent decarboxylation of mevalonate pyrophosphate to form isopentenyl pyrophosphate <ref type="bibr" target="#b8">(Hinson et al., 1997;</ref><ref type="bibr" target="#b13">Michihara et al., 2001)</ref>. We found that MVD was increased in Fdx1-deficient cells (Figure <ref type="figure" target="#fig_3">3E</ref> and<ref type="figure">F</ref>), indicating that the mature nuclear form of SREBP2 protein induced by Fdx1 deficiency is transcriptionally active.</p><p>Next, we used HCT116 human colorectal cancer cells to determine if the effect of FDX1 on lipid metabolism observed in murine cells is conserved in human cells. We again employed the CRIS-PR-Cas9 system to knock out the FDX1 gene in HCT116 cells <ref type="bibr" target="#b38">(Zhang et al., 2017)</ref>. Surprisingly, unlike murine cells, we were able to obtain complete knock-out of FDX1 in human cells (Figure <ref type="figure" target="#fig_4">4A</ref>). Nevertheless, we found that like in murine cells, loss of FDX1 led to increased activation of the SREBP1/ SREBP2 pathways in HCT116 cells (Figure <ref type="figure" target="#fig_4">4B-C</ref>). Furthermore, lipid droplets were increased in the FDX1-KO HCT116 cells compared to isogenic control cells (Figure <ref type="figure" target="#fig_4">4D</ref>). Since Nile Red is not specific to certain lipids and can recognize several intracellular neutral lipids, including TAGs <ref type="bibr" target="#b6">(Greenspan et al., 1985)</ref> and sterol esters/cholesterol esters (CEs) <ref type="bibr" target="#b5">(Genicot et al., 2005)</ref>, in vitro enzymatic assays were performed to specifically measure the levels of TAGs and cholesterol in these cells. We found that the intracellular levels of both cholesterol and TAGs were significantly upregulated in FDX1-KO HCT116 cells compared to isogenic control cells (Figure <ref type="figure" target="#fig_4">4E</ref> and F), confirming aberrant lipid metabolism upon loss of FDX1.</p><p>As loss of FDX1 promotes lipid droplet accumulation, we wanted to investigate if overexpression of FDX1 would decrease lipid droplet accumulation. To test this, FDX1 was inducibly expressed under the control of the doxycycline-regulated promoter in HCT116 cells. Treatment with doxycycline led to robust overexpression of FDX1 in these cells (Figure <ref type="figure" target="#fig_4">4</ref>-figure <ref type="figure" target="#fig_8">supplement 1A</ref>). Next, we examined lipid droplet accumulation in these cells with or without FDX1 induction using Nile red staining. We found that overexpression of FDX1 decreased lipid droplet accumulation (Figure <ref type="figure" target="#fig_4">4</ref>-figure supplement 1B). Together, we demonstrated that FDX1 is involved in lipid metabolism possibly via SREBP1/2 pathways in both murine and human cells.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Loss of FDX1 alters the lipidome in HCT116 cells</head><p>As loss of FDX1 appeared to alter lipid metabolism, we wanted to examine which classes of lipids are altered by FDX1 deficiency. For this, untargeted lipidomic analysis was performed with isogenic control and FDX1-KO HCT116 cells. A total of 710 lipids were identified and quantified by LC-MS/MS, including cholesterol, TAGs, fatty acids, cardiolipins, acylcarnitines (CARs), ceramides (CERs), various phospholipids and lysophospholipids. Consistent with the data measured by the enzymatic assay (Figure <ref type="figure" target="#fig_4">4D</ref>), untargeted lipidomic analysis showed that the levels of cholesterol were highly increased in FDX1-deficient cells as compared to that in isogenic control cells (Figure <ref type="figure" target="#fig_7">5A</ref> and Figure <ref type="figure" target="#fig_7">5</ref>-figure <ref type="figure" target="#fig_8">supplement 1A</ref>). In addition, loss of FDX1 led to a significant increase in the content of acylcarnitines (CARs) and phosphotidylcholines (PCs) (Figure <ref type="figure" target="#fig_7">5C</ref>-D; Figure <ref type="figure" target="#fig_7">5</ref>-figure <ref type="figure" target="#fig_8">supplement 1B-C</ref>) but a marked decrease in lysophosphotidylcholine (LPCs), lysophosphotidylethanolamine (LPEs) and ceramides (CERs) (Figure <ref type="figure" target="#fig_7">5E</ref>-G; Figure <ref type="figure" target="#fig_7">5</ref>-figure <ref type="figure" target="#fig_8">supplement 1D-F</ref>). On the other hand, we did not observe any significant difference in the levels of phosphotidylethanolamines (PEs), cardiolipins, sphingomyelins (SMs), fatty acids (FAs), and diacylglycerols (DAGs) (Figure <ref type="figure" target="#fig_7">5H-L</ref>). Interestingly, while the level of TAGs was found to be increased by the enzymatic assay (Figure <ref type="figure" target="#fig_4">4E</ref>; Figure <ref type="figure" target="#fig_7">5</ref>-figure supplement 1G), the level of TAGs was found to be decreased by untargeted lipidomic analysis (Figure <ref type="figure" target="#fig_7">5B</ref>; Figure <ref type="figure" target="#fig_7">5</ref>-figure supplement 1G), suggesting that glycerols from other complex lipids may have been recognized by the enzymatic assay as TAGs <ref type="bibr" target="#b12">(Kapoor and Gupta, 2012;</ref><ref type="bibr" target="#b7">Haupt and</ref> Source data 1. Kaplan-Meier survival analysis for various mice cohorts in Figure <ref type="figure" target="#fig_2">2A</ref>.</p><p>Source data 2. Analysis, graphs, and statistical significance for Figure <ref type="figure" target="#fig_2">2C</ref> and<ref type="figure">E</ref>.</p><p>Source data 3. Wild type (WT) mice (n=56) -survival time, tumor spectrum, steatosis, inflammation, and other abnormalities (A); Fdxr+/-mice (n=31) -survival time, tumor spectrum and other abnormalities (B); Fdx1+/-mice (n=26) -survival time, tumor spectrum, steatosis, inflammation, and other abnormalities (C).      Valley, 2020). Together, these data indicate that FDX1-KO leads to significant alterations in lipid profile due to aberrant lipid metabolism.</p><note type="other">Figure 2 continued</note></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>FDX1/2 transduce an electron from FDXR to various effector protein complexes. FDX1 is suggested to be involved in sterol hydroxylation and cholesterol side chain cleavage <ref type="bibr" target="#b25">(Schulz et al., 2023)</ref>. Recent studies indicate that FDX1 plays a critical role in the regulation of oxidative phosphorylation via lipoylation of key TCA cycle enzymes <ref type="bibr" target="#b25">(Schulz et al., 2023;</ref><ref type="bibr" target="#b34">Tsvetkov et al., 2022)</ref>. Although FDX1 has been extensively characterized biochemically, its role in physiology and lipid metabolism has not been explored. In this study, we generated mice deficient in Fdx1 and showed that homozygous Fdx1 deletion led to embryonic lethality at E10.5. We also showed that Fdx1 +/-+/-had a short life span and developed steatohepatitis, which is similar to the phenotypes exhibited by Fdxr +/-+/-. Moreover, Fdx1 deficiency led to lipid droplet accumulation in both murine and human cells, possibly via the ABCA1-SREBP1/2 pathways. Consistently, untargeted lipidomic analysis showed that FDX1 deficiency led to alterations in several classes of lipids, suggesting the role of FDX1 in lipid metabolism.</p><p>The embryonic lethality by complete loss of Fdx1 is similar to what we previously showed by complete loss of Fdxr, the latter of which was attributed in part to iron overload <ref type="bibr" target="#b38">(Zhang et al., 2017)</ref>. However, as FDX1 is not a major player in Fe-S cluster synthesis <ref type="bibr" target="#b25">(Schulz et al., 2023)</ref>, the lethality could be due to lack of progesterone production by placenta, which is required for the maintenance of pregnancy <ref type="bibr" target="#b14">(Miller and Auchus, 2011)</ref>. Thus, Fdx1 -/-embryos would not be able to survive due to a miscarriage. However, since mice with complete deletion of Cyp11a1 (Cytochrome p450scc), which is essential for progesterone production, can survive till birth <ref type="bibr" target="#b10">(Hu et al., 2002)</ref>, we postulate that other pathways may be responsible for the lethality of Fdx1 -/-embryos. Additionally, since Fdx1 -/-embryos developed abnormally, we postulate that FDX1 may be required for proper embryo growth, consistent with a recent observation that loss of FDX1 would lead to defects in lipoylation of key TCA cycle enzymes and subsequent loss of oxidative phosphorylation <ref type="bibr" target="#b25">(Schulz et al., 2023;</ref><ref type="bibr" target="#b34">Tsvetkov et al., 2022)</ref>.</p><p>We observed that Fdx1 +/-+/-were not prone to spontaneous tumors, which is different from tumorprone Fdxr +/-+/- <ref type="bibr" target="#b39">(Zhang et al., 2022;</ref><ref type="bibr" target="#b38">Zhang et al., 2017)</ref>. Nevertheless, Fdx1 +/-+/-exhibited a higher incidence of adenocarcinomas and sarcomas compared to WT mice (Figure <ref type="figure" target="#fig_1">2</ref>). One possible explanation is that loss of Fdxr leads to decreased expression of p53 tumor suppressor whereas loss of Fdx1 alone does not have a significant effect on p53 expression <ref type="bibr" target="#b38">(Zhang et al., 2017)</ref>. We also observed that murine cells deficient in both alleles of the Fdx1 gene are not viable, which is consistent with the observation that Fdx1-KO embryos die between 10.5 and 13.5 days post-fertilization (Figure <ref type="figure" target="#fig_0">1</ref>). However, both our own and others' published studies showed that FDX1-KO human cells are viable <ref type="bibr" target="#b25">(Schulz et al., 2023;</ref><ref type="bibr" target="#b34">Tsvetkov et al., 2022;</ref><ref type="bibr" target="#b38">Zhang et al., 2017)</ref>. One possible explanation is that human FDX2, but not murine Fdx2, may be able to compensate for loss of FDX1 for cell survival, which is worth further investigation.</p><p>Murine and human cells deficient in FDX1 showed increased lipid accumulation possibly via activation of the ABCA1-SREBP1/2 pathways, which was again consistent with the loss of FDXR <ref type="bibr" target="#b39">(Zhang et al., 2022)</ref>. In order to identify specific classes of lipids altered upon loss of FDX1, lipidomic analysis was performed and showed that the levels of cholesterol, triacylglycerols, acylcarnities, phospholipids, and lysophospholipids were significantly altered by the loss of FDX1. Thus, altered lipid metabolism is likely responsible for steatohepatitis observed in Fdx1-deficient mice. Steatohepatis is a progressive disease that initiates with the accumulation of excessive fat in the liver (steatosis; <ref type="bibr" target="#b27">Shao et al., 2020;</ref><ref type="bibr" target="#b35">Vanni et al., 2010)</ref>. The fat accumulation would induce liver inflammation, leading to steatohepatitis, referred to as non-alcoholic steatohepatitis (NASH). These data clearly indicate that FDX1 is involved in cellular and physiological lipid homeostasis and that loss of FDX1 leads to development of pathological impairment in mice. Although previous studies showed that FDX1 is involved in cholesterol metabolism, the observations in this study raise a critical question about how FDX1 regulates the metabolism of the various classes of lipids. Thus, further studies are warranted to address this issue.</p><p>Aberrant lipid metabolism has emerged as a key player in the intricate landscape of oncogenesis, contributing to the development and progression of various cancers <ref type="bibr" target="#b24">(Santos and Schulze, 2012)</ref>. Aberrant regulation of lipid metabolism pathways, such as altered fatty acid synthesis, increased cholesterol metabolism, and disrupted lipid signaling, have been implicated in tumorigenesis <ref type="bibr" target="#b11">(Huang et al., 2020)</ref>. Additionally, aberrant lipid metabolism can influence signaling pathways crucial for cell proliferation, survival, and migration <ref type="bibr" target="#b0">(Broadfield et al., 2021)</ref>. Although, the overall tumor penetrance in Fdx1 +/-+/-not significantly altered as compared to WT mice, we indeed observed increased incidences of adenocarcinomas in these mice, which would signal the role of Fdx1-mediated lipid homeostasis in regulation of oncogenesis and warrants further studies.</p><p>In conclusion, we showed that FDX1 is essential for mammalian embryonic development and is also critical for the maintenance of lipid homeostasis at cellular and physiological levels.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fdx1 mutant mouse model</head><p>The use of animals and the study protocols used in this article were approved by the University of California at Davis Institutional Animal Care and Use Committee under the protocol # 23011. Fdx1 +/- +/-were generated by the Mouse Biology Program at the University of California, Davis (Davis, CA, USA). The Fdx1 +/-+/-used in this study as well as the WT and Fdxr +/-mice used in the previous studies were all derived from and maintained in C57BL/6 background. The primers used to genotype the Fdx1-WT allele are forward primer, 5'-GGT GTA GTG TGG TGG TCA AGT ATG TG-3', and reverse primer, 5'-CAC ACC GAG GAC ATA CTC TCT CAC-3'; and for Fdx1-KO allele are forward primer, 5'-GGT GTA GTG TGG TGG TCA AGT ATG TG-3', and reverse primer, 5'-CTC CTA CAT AGT TGG CAG TGT TTG GG-3'.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MEF isolation</head><p>MEFs were isolated from 12.5 to 13.5 days post-coitum (pc) mouse embryos, as described previously <ref type="bibr" target="#b17">(Mohibi et al., 2023;</ref><ref type="bibr" target="#b16">Mohibi et al., 2021)</ref>. To generate WT and Fdx1 +/-+/-, Fdx1 +/-+/-were interbred. The MEFs were cultured in DMEM supplemented with 10% FBS (Hyclone Laboratories, Erie, PA, USA), 55 Î¼M Î²-mercaptoethanol and 1 x non-essential amino acids solution (Cellgro, Manassas, VA, USA).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell culture</head><p>SCp2 mouse mammary epithelial cells were kindly provided by Pierre-Yves Desprez at the California Pacific Medical Center Research Institute and cultured as previously described <ref type="bibr" target="#b3">(Desprez et al., 1998)</ref>. Mouse normal liver FL83B cells and the human cancer cell line HCT116 were acquired from ATCC between 2007 and 2018 and utilized at passages below 20 or within 2 months of thawing. Authentication and Mycoplasma testing were not conducted since ATCC had already authenticated and tested these cell lines. This decision was particularly based on the low passages at which the cell lines were employed. FL83B and HCT116 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) supplemented with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Plasmid construction and cell line generation</head><p>To generate Fdx1-KO murine cells, two single-guide RNA (sgRNA) expression vectors pSpCas9(BB)-2A-Puro-sgFdx1-1 and pSpCas9(BB)-2A-Puro-sgFdx1-2 were used to remove initiation codon in exon 1 and create frame shift deletions. The generation of sgRNA expression vector was performed as described previously <ref type="bibr" target="#b22">(Ran et al., 2013)</ref>. The oligonucleotides for sgFdx1-1 are sense, 5'-CAC CGG GAC CCG GAA CCT TCC GAC -3', and antisense, 5'-AAA CGT CGG AAG GTT CCG GGT CCC -3'; for sgFdx1-2 are sense, 5'-CAC CGT CCG CGG CCT TGA CCG CTG T -3', and antisense, 5'-AAA CAC AGC GGT CAA GGC CGC GGA C -3'.</p><p>Generation of Fdx1 +/-+/-2 and FL83B cell lines was achieved by transfecting the above guides in these cells using JetPRIME transfection reagent. The cells were selected with puromycin, and individual clones picked, genotyped, sequenced, and confirmed by western blot analysis. The primers used for genotyping mouse Fdx1 were: forward primer, 5'-TTA TAG GAC ACG CAG GGC -3', and reverse primer, 5'-ACG GAG AGA TGG CAG TTC -3'. The generation of FDX1-KO HCT116 has been described previously <ref type="bibr" target="#b38">(Zhang et al., 2017)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Western blot analysis</head><p>Western blotting was performed as previously described <ref type="bibr" target="#b15">(Mohibi et al., 2020)</ref>. Briefly, cell lysates were collected as indicated, resolved on 8-11% SDS-polyacrylamide gels and transferred to nitrocellulose membrane. After the transfer, the membranes were blocked with PBST containing 2.5% milk at room temperature (RT) for 1hr, followed by overnight 4 Â°C incubation with primary antibodies prepared in 2.5% milk containing PBST. The following day, after 3 X washings with PBST, the blots were incubated at room temperature for 1 hr in secondary antibody prepared in PBST containing 2.5% milk. After 3 X washings with PBST, the blots were soaked in enhanced chemiluminescence reagents (Thermo Fisher Scientific), and then visualized with the BioSpectrum 810 Imaging System (UVP LLC, Upland, CA). The blots from at least three independent experiments were quantified by ImageJ using standard protocol (ImageJ.pdf yorku.ca). Antibody against human/mouse ABCA1 (#PA1-16789; RRID:AB_2288917) was purchased from Invitrogen Life Technologies (Carlsbad, CA) and Cell signaling technology (#96292, Danvers, MA). Antibodies against SREBP1 (#ab3259; RRID:AB_303650), SREBP2 (#ab30682; RRID:AB_779079; used to detect human SREBP2) and FDX1 (#ab108257) were purchased from Abcam (Cambridge, MA). Antibody against SREBP2 (#MAB7119, to detect mouse SREBP2) was purchased from R&amp;D systems (Minneapolis, MN). Antibody against FDXR (#sc-374436) was purchased from Santa Cruz Biotechnology (Dallas, TX). HRP-conjugated secondary antibodies against rabbit and mouse IgG were purchased from BioRad (Hercules, CA).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RNA isolation and RT-PCR analysis</head><p>Total RNA was harvested using TRIzol reagent (Invitrogen) and isolated according to the manufacturer's instructions. RevertAid First Strand cDNA Synthesis kit (Thermo Fisher Scientific) was used to synthesize cDNA from 2 Î¼g total RNA as per manufacturer's protocol. The primers used to amplify mouse AFP were forward primer, 5'-AGG AGG AGT GCT TCC AGA CA -3', and reverse primer, 5'-TGC GTG AAT TAT GCA GAA GC -3'. The primers used to amplify mouse actin were forward primer, 5'-TCC ATC ATG AAG TGT GAC GT-3', and reverse primer, 5'-TGA TCC ACA TCT GCT GGA AG-3'.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Nile Red staining</head><p>Nile Red (#ab219403) was purchased from Abcam (Cambridge, MA). A 10 ÂµM stock solution of Nile red was prepared by dissolving it in acetone. Nile red was diluted to 2 Âµg/mL in complete medium and added to the cells for 30 min at room temperature. Subsequently, the cells were washed with PBS and fixed in 4% paraformaldehyde (Sigma Aldrich, St Louise, MO) for 20 min at room temperature. The cells were then counterstained with DAPI and images were obtained using with confocal microscope.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Measurement of cellular cholesterol and triglycerides</head><p>Total cholesterol and triglycerides from cells were determined by using Cholesterol/Cholesterol Ester-Glow assay kit (Promega, Madison, WI) and Triglyceride-Glow assay kit (Promega, Madison, WI), respectively. Briefly, cells were plated in 96-well plate. After 4 hr of fasting in serum-free media, the levels of cholesterol and triglycerides were measured according to manufacturer's protocol.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Histological analysis</head><p>Wild-type, Fdxr +/-, and Fdx1 +/-mouse tissues were fixed in 10% (w/v) neutral buffered formalin, processed, and embedded in paraffin blocks. Embedded tissues were sectioned (6 Âµm) and stained with H&amp;E.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Untargeted lipidomic analysis using LC-MS/MS</head><p>Lipids were extracted and analyzed by reversed-phase liquid chromatography tandem mass spectrometry (RPLC-MS/MS) at West Coast Metabolomics Center with published methods <ref type="bibr" target="#b4">(Ding et al., 2021)</ref>. Thirty million isogenic control or FDX1-KO HCT116 cells were harvested and analyzed for lipidomics as previously described <ref type="bibr" target="#b21">(Rabow et al., 2022)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p>The data were presented as Mean Â± SEM or Mean Â± SD as indicated. Statistical significance was determined by two-tailed Student's t test. Values of p&lt;0.05 were considered significant. For Kaplan-Meyer survival analysis, log-rank test was performed. Fisher's exact test was used for comparison of tumors, adenocarcinomas, and liver steatosis/steatohepatitis from different mice cohorts.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc>Figure 1. Fdx1 knock-out mouse are embryonically lethal. (A) Schematic diagram of the targeted Fdx1 gene locus and the cassette used to target the locus using a knock-out first approach. (B) Representative image of a PCR gel used to genotype WT and Fdx1 +/-+/-. (C) The number and % of embryos and live off-springs from the intercrosses of Fdx1 +/-+/-. (D) Representative images of WT, Fdx1 +/-, and Fdx1 -/-embryos obtained at embryonic day 10.5. The white dots seen in the pictures are the result of light reflection while taking the photos. (E) Agarose gel image of a PCR used to genotype WT, Fdx1 +/-, and Fdx1 -/-embryos shown in (D).</figDesc><graphic coords="3,42.63,60.13,526.00,460.28" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc>Figure 2. Fdx1 +/-+/-have shorter life-span and increased incidence of adenocarcinoma and steatohepatitis. (A) Kaplan-Meier survival curves of WT (n=56), Fdxr +/-(n=31), and Fdx1 +/-(n=26) mice. (B) Tumor spectra and penetrance in WT, Fdxr +/-, and Fdx1 +/-+/-. (C) The numbers and percentages of WT, Fdxr +/-, and Fdx1 +/-+/-with adenocarcinoma. (D) Representative images of hematoxylin and eosin (H&amp;E)-stained adenocarcinomas from Fdx1+/-mice. The images are of gastrointestinal tract-associated adenocarcinoma in mouse #5-20-1, whereas they are of lung adenocarcinoma in mice #10-21-20 and #7-24-14. (E) The numbers and percentages of WT, Fdxr +/-, and Fdx1 +/-+/-with liver steatosis/steatohepatitis. (F) Representative images of hematoxylin and eosin (H&amp;E)-stained WT and Fdx1 +/-+/-showing steatosis in Fdx1-deficient mice. The online version of this article includes the following source data for figure 2:</figDesc><graphic coords="5,42.63,60.13,526.00,553.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 2</head><label>2</label><figDesc>Figure 2 continued on next page</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 3 .</head><label>3</label><figDesc>Figure 3. Lack of FDX1 leads to altered lipid metabolism possibly via ABCA1-SREBP1/2 pathways in murine cells. (A) The levels of Fdx1 and Actin were measured in two sets of WT and Fdx1 +/-+/-. (B) Lipid droplets were visualized with Nile Red staining (ex: 488 nm, em: 565 nm) in WT and Fdx1 +/- +/-cultured in serum-free media for 4 hr. DAPI (ex: 358 nm, em: 461 nm) was used to stain nuclei. (C, G) The levels of Fdx1, Fdxr and Actin protein were measured by immunoblotting in isogenic control and two Fdx1 +/-+/-83 B cells (D) or SCp2 cells (G). (D, I) Isogenic control and two Fdx1 +/-+/-83B clones (clone#53 and #22) (E) or isogenic control and two Fdx1 +/-+/-2 clones (clone#4 and #26) were cultured in serum-free media for 4 hr followed by Nile Red staining. DAPI was used to stain nuclei. (E) The levels of ABCA1, SREBP1/2, MVD, and Actin were measured in isogenic control and Fdx1 +/-+/-83B cells cultured in serum-free media for 4 hr. (F, H) Quantification of Western blot bands from E (F) or G (H) using ImageJ. The graphs show relative fold change of the indicated proteins from at least three independent experiments. Data represent the mean Â± SEM. The online version of this article includes the following source data for figure 3: Source data 1. Unedited western blot images for Figure 3A, C, E and G. Source data 2. ImageJ analysis and statistical significance for Figure 3F and H.</figDesc><graphic coords="7,42.63,60.13,451.20,495.60" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 4 .</head><label>4</label><figDesc>Figure 4. Lack of FDX1 leads to altered lipid metabolism possibly via SREBP1/2 pathways in human cells. (A) The levels of FDX1 and Actin protein were measured by immunoblotting in isogenic control and FDX1 -/-HCT116 cells. (B) The levels of SREBP1/2, MVD, and Actin were measured in isogenic control and FDX1 -/-HCT116 cells cultured in serum-free media for 4 hr. (C) Quantification of Western blot bands from (B) using ImageJ. The graph shows relative fold change of the indicated proteins from at least 3 independent experiments. Data represent the mean Â± SEM. (D) Lipid droplets were visualized with Nile Red staining (ex: 488 nm, em: 565 nm) in isogenic control and two FDX1 -/-HCT116 clones (clone#18 and #19) cultured in serum-free media for 4 hr. DAPI (ex: 358 nm, em: 461 nm) was used to stain nuclei. (E) Quantitative measurement of intracellular cholesterol esters. Isogenic control and FDX1 -/-HCT116 cells were cultured in a 96-well plate. After 4 hr of fasting, the level of total cholesterol was measured with Cholesterol/Cholesterol Ester-GloTM assay kit according to manufacturer's instruction. Data represent the mean Â± SD. (F) Quantitative measurement of intracellular triglycerides. Isogenic control and FDX1 -/-HCT116 cells were cultured in a 96-well plate. After 4 hr of fasting, the level of total triglycerides was measured with Triglyceride-GloTM assay kit according to manufacturer's instruction. Data represent the mean Â± SD. The online version of this article includes the following source data and figure supplement(s) for figure 4: Source data 1. Unedited western blot images for Figure 4A and B. Source data 2. ImageJ analysis and statistical significance for Figure 4C. Source data 3. Analysis, graphs, and statistical significance for Figure 4E and F.</figDesc><graphic coords="8,42.63,60.13,451.68,363.60" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure supplement 1 .</head><label>1</label><figDesc>Figure supplement 1. Over-expression of FDX1 leads to decrease in cytoplasmic lipid droplets in human cells.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Figure supplement 1</head><label>1</label><figDesc>Figure supplement 1-source data 1. Unedited western blot images for Figure 1A.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>Figure 5 .</head><label>5</label><figDesc>Figure 5. Lack of FDX1 leads to alterations in the lipid profile. Isogenic control and FDX1-KO HCT116 cells were used for lipidomic analysis by LC-MS/MS. The relative abundance of a lipid was calculated as mean Â± SEM and statistical significance was determined using Student's t-test. (A) Cholesterol; (B) Triacylglycerides (TAGs); (C) Acylcarnitines (CARs); (D) Phosphatidylcholines (PCs); (E) Lysophosphatidylcholines (LPCs); (F) Lysophosphatidylethanolamines (LPEs); (G) Ceramides (CERs); (H) Phosphatidylethanolamines (PEs); (I) Cardiolipins; (J) Sphingomyeline (SMs); (K) Fatty acids (FAs); (L) Diacylglycerols (DAGs). The online version of this article includes the following source data and figure supplement(s) for figure 5: Source data 1. Relative lipid classes abundance, analysis, graphs and statistical significance for Figure 5A-L.</figDesc><graphic coords="9,42.63,60.13,525.60,538.88" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_8"><head>Figure supplement 1 .</head><label>1</label><figDesc>Figure supplement 1. Lack of FDX1 leads to alterations in the lipid profile.</figDesc></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p>Mohibi, Zhang et al. eLife 2024;13:e91656. DOI: https://doi.org/10.7554/eLife.91656</p></note>
		</body>
		<back>

			
			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head></div>
			</div>


			<div type="funding">
<div><head>Grant reference number Author</head></div>
<div><head>National Institutes of Health</head></div>
<div><head>CA224433</head><p>Xinbin Chen</p><p>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</p></div>
			</div>			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Additional files</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary files â¢ MDAR checklist</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data availability</head><p>The authors confirm that the data supporting the findings of this study are available within the article, its supplementary materials and source data files.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Lipid metabolism in cancer: new perspectives and emerging mechanisms</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Broadfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Pane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Talebi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Swinnen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Fendt</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.devcel.2021.04.013</idno>
		<idno type="PMID">33945792</idno>
		<ptr target="https://doi.org/10.1016/j.devcel.2021.04.013" />
	</analytic>
	<monogr>
		<title level="j">Developmental Cell</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="1363" to="1393" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Goldstein</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0092-8674(00)80213-5</idno>
		<idno type="PMID">9150132</idno>
		<ptr target="https://doi.org/10.1016/s0092-8674(00)80213-5" />
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="331" to="340" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">An overview of deregulated lipid metabolism in nonalcoholic fatty liver disease with special focus on lysosomal acid lipase</title>
		<author>
			<persName><forename type="first">S</forename><surname>Carotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Aquilano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Valentini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ruggiero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Alletto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Morini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Picardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Antonelli-Incalzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lettieri-Barbato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Vespasiani-Gentilucci</surname></persName>
		</author>
		<idno type="DOI">10.1152/ajpgi.00049.2020</idno>
		<idno type="PMID">32812776</idno>
		<ptr target="https://doi.org/10.1152/ajpgi.00049.2020" />
	</analytic>
	<monogr>
		<title level="j">American Journal of Physiology. Gastrointestinal and Liver Physiology</title>
		<imprint>
			<biblScope unit="volume">319</biblScope>
			<biblScope unit="page" from="469" to="G480" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">A novel pathway for mammary epithelial cell invasion induced by the helix-loop-helix protein Id-1</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">Y</forename><surname>Desprez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Q</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Thomasset</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Sympson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Bissell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Campisi</surname></persName>
		</author>
		<idno type="DOI">10.1128/MCB.18.8.4577</idno>
		<idno type="PMID">9671467</idno>
		<ptr target="https://doi.org/10.1128/MCB.18.8.4577" />
	</analytic>
	<monogr>
		<title level="j">Molecular and Cellular Biology</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="4577" to="4588" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">A metabolome atlas of the aging mouse brain</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Rabow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Folz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Brydges</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Fan</forename><forename type="middle">S</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Mehta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Showalter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Araiza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bower</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Lloyd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kck</forename><surname>Fiehn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename></persName>
		</author>
		<idno type="DOI">10.1038/s41467-021-26310-y</idno>
		<idno type="PMID">34654818</idno>
		<ptr target="https://doi.org/10.1038/s41467-021-26310-y" />
	</analytic>
	<monogr>
		<title level="j">Nature Communications</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">6021</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">The use of a fluorescent dye, nile red, to evaluate the lipid content of single mammalian oocytes</title>
		<author>
			<persName><forename type="first">G</forename><surname>Genicot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Leroy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Soom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Donnay</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.theriogenology.2004.06.006</idno>
		<idno type="PMID">15710202</idno>
		<ptr target="https://doi.org/10.1016/j.theriogenology.2004.06.006" />
	</analytic>
	<monogr>
		<title level="j">Theriogenology</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="1181" to="1194" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Nile red: a selective fluorescent stain for intracellular lipid droplets</title>
		<author>
			<persName><forename type="first">P</forename><surname>Greenspan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Mayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Fowler</surname></persName>
		</author>
		<idno type="DOI">10.1083/jcb.100.3.965</idno>
		<idno type="PMID">3972906</idno>
		<ptr target="https://doi.org/10.1083/jcb.100.3.965" />
	</analytic>
	<monogr>
		<title level="j">The Journal of Cell Biology</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="965" to="973" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Homogeneous assays for triglyceride metabolism research</title>
		<author>
			<persName><forename type="first">K</forename><surname>Haupt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Valley</surname></persName>
		</author>
		<ptr target="https://www.promega.com/resources/pubhub/2020/homogeneous-assays-for-triglyceride-metabolism-research-technical-article/" />
	</analytic>
	<monogr>
		<title level="j">Promega UK</title>
		<imprint>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Post-translational regulation of mevalonate kinase by intermediates of the cholesterol and nonsterol isoprene biosynthetic pathways</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Hinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Chambliss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Toth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Gibson</surname></persName>
		</author>
		<idno type="PMID">9392419</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Lipid Research</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="2216" to="2223" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Tumour fatty acid metabolism in the context of therapy resistance and obesity</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Hoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Nagarajan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Butler</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41568-021-00388-4</idno>
		<idno type="PMID">34417571</idno>
		<ptr target="https://doi.org/10.1038/s41568-021-00388-4" />
	</analytic>
	<monogr>
		<title level="j">Nature Reviews. Cancer</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="753" to="766" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Steroid deficiency syndromes in mice with targeted disruption of Cyp11a1</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">El</forename><surname>Hadj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">B</forename><surname>Pai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">I</forename><surname>Chu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ckl</forename><surname>Chung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename></persName>
		</author>
		<idno type="DOI">10.1210/me.2002-0055</idno>
		<idno type="PMID">12145347</idno>
		<ptr target="https://doi.org/10.1210/me.2002-0055" />
	</analytic>
	<monogr>
		<title level="j">Molecular Endocrinology</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="1943" to="1950" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities</title>
		<author>
			<persName><forename type="first">B</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Xu</surname></persName>
		</author>
		<idno type="DOI">10.1038/s42255-020-0174-0</idno>
		<idno type="PMID">32694690</idno>
		<ptr target="https://doi.org/10.1038/s42255-020-0174-0" />
	</analytic>
	<monogr>
		<title level="j">Nature Metabolism</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="132" to="141" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Lipase promiscuity and its biochemical applications</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kapoor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Gupta</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.procbio.2012.01.011</idno>
		<ptr target="https://doi.org/10.1016/j.procbio.2012.01.011" />
	</analytic>
	<monogr>
		<title level="j">Process Biochemistry</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="555" to="569" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Tissue distribution of a major mevalonate pyrophosphate decarboxylase in rats</title>
		<author>
			<persName><forename type="first">A</forename><surname>Michihara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Akasaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yamori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tsuji</surname></persName>
		</author>
		<idno type="DOI">10.1248/bpb.24.1231</idno>
		<idno type="PMID">11725954</idno>
		<ptr target="https://doi.org/10.1248/bpb.24.1231" />
	</analytic>
	<monogr>
		<title level="j">Biological &amp; Pharmaceutical Bulletin</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1231" to="1234" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">L</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Auchus</surname></persName>
		</author>
		<idno type="DOI">10.1210/er.2010-0013</idno>
		<idno type="PMID">21051590</idno>
		<ptr target="https://doi.org/10.1210/er.2010-0013" />
	</analytic>
	<monogr>
		<title level="j">Endocrine Reviews</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="81" to="151" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Pabpn1, a target of p63, modulates keratinocyte differentiation through regulation of p63Î± mrna translation</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mohibi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jid.2020.03.942</idno>
		<idno type="PMID">32243883</idno>
		<ptr target="https://doi.org/10.1016/j.jid.2020.03.942" />
	</analytic>
	<monogr>
		<title level="j">The Journal of Investigative Dermatology</title>
		<imprint>
			<biblScope unit="volume">140</biblScope>
			<biblScope unit="page" from="2166" to="2177" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Mice deficient in the rna-binding protein zfp871 are prone to early death and steatohepatitis in part through the p53-mdm2 axis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mohibi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1158/1541-7786.MCR-21-0239</idno>
		<idno type="PMID">34257081</idno>
		<ptr target="https://doi.org/10.1158/1541-7786.MCR-21-0239" />
	</analytic>
	<monogr>
		<title level="j">Molecular Cancer Research</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1751" to="1762" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Poly zinc finger protein zfp14 suppresses lymphomagenesis and abnormal inflammatory response via the hoxa gene cluster</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mohibi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bbadis.2022.166587</idno>
		<idno type="PMID">36349645</idno>
		<ptr target="https://doi.org/10.1016/j.bbadis.2022.166587" />
	</analytic>
	<monogr>
		<title level="j">Biochimica et Biophysica Acta. Molecular Basis of Disease</title>
		<imprint>
			<biblScope unit="volume">1869</biblScope>
			<biblScope unit="page">166587</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">P53 represses the mevalonate pathway to mediate tumor suppression</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Moon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Houlihan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Regunath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Freed-Pastor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Tschaharganeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Kastenhuber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Barsotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Culp-Hill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Xue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Baslan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mayle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>De Stanchina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>'alessandro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lowe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.cell.2018.11.011</idno>
		<idno type="PMID">30580964</idno>
		<ptr target="https://doi.org/10.1016/j.cell.2018.11.011" />
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">176</biblScope>
			<biblScope unit="page" from="564" to="580" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Evolutionary conservation and adaptation in the mechanism that regulates SREBP action: what a long, strange tRIP it&apos;s been</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Osborne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Espenshade</surname></persName>
		</author>
		<idno type="DOI">10.1101/gad.1854309</idno>
		<idno type="PMID">19933148</idno>
		<ptr target="https://doi.org/10.1101/gad.1854309" />
	</analytic>
	<monogr>
		<title level="j">Genes &amp; Development</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="2578" to="2591" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">An overview of lipid metabolism and nonalcoholic fatty liver disease</title>
		<author>
			<persName><forename type="first">K</forename><surname>Pei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jin</forename><forename type="middle">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Gai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename></persName>
		</author>
		<idno type="DOI">10.1155/2020/4020249</idno>
		<idno type="PMID">32733940</idno>
		<ptr target="https://doi.org/10.1155/2020/4020249" />
	</analytic>
	<monogr>
		<title level="j">BioMed Research</title>
		<imprint>
			<biblScope unit="volume">2020</biblScope>
			<biblScope unit="page">4020249</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">P73Î±1, an isoform of the p73 tumor suppressor, modulates lipid metabolism and cancer cell growth via stearoyl-coa desaturase-1</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Rabow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Laubach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Kong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mohibi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Fiehn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.3390/cells11162516</idno>
		<idno type="PMID">36010592</idno>
		<ptr target="https://doi.org/10.3390/cells11162516" />
	</analytic>
	<monogr>
		<title level="j">Cells</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">2516</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Genome engineering using the CRISPR-Cas9 system</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Ran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Agarwala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.1038/nprot.2013.143</idno>
		<idno type="PMID">24157548</idno>
		<ptr target="https://doi.org/10.1038/nprot.2013.143" />
	</analytic>
	<monogr>
		<title level="j">Nature Protocols</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="2281" to="2308" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Nonalcoholic steatohepatitis: A search for factual animal models</title>
		<author>
			<persName><forename type="first">Scl</forename><surname>Sanches</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lnz</forename><surname>Ramalho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Augusto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Da Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">S</forename><surname>Ramalho</surname></persName>
		</author>
		<idno type="DOI">10.1155/2015/574832</idno>
		<idno type="PMID">26064924</idno>
		<ptr target="https://doi.org/10.1155/2015/574832" />
	</analytic>
	<monogr>
		<title level="j">BioMed Research International</title>
		<imprint>
			<biblScope unit="page">574832</biblScope>
			<date type="published" when="2015">2015. 2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Lipid metabolism in cancer</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schulze</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1742-4658.2012.08644.x</idno>
		<idno type="PMID">22621751</idno>
		<ptr target="https://doi.org/10.1111/j.1742-4658.2012.08644.x" />
	</analytic>
	<monogr>
		<title level="j">The FEBS Journal</title>
		<imprint>
			<biblScope unit="volume">279</biblScope>
			<biblScope unit="page" from="2610" to="2623" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Functional spectrum and specificity of mitochondrial ferredoxins FDX1 and FDX2</title>
		<author>
			<persName><forename type="first">V</forename><surname>Schulz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Basu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Freibert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Webert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Boss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>MÃ¼hlenhoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Pierrel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">O</forename><surname>Essen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Warui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Booker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Stehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lill</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41589-022-01159-4</idno>
		<idno type="PMID">36280795</idno>
		<ptr target="https://doi.org/10.1038/s41589-022-01159-4" />
	</analytic>
	<monogr>
		<title level="j">Nature Chemical Biology</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="206" to="217" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Expanding roles for SREBP in metabolism</title>
		<author>
			<persName><forename type="first">W</forename><surname>Shao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Espenshade</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cmet.2012.09.002</idno>
		<idno type="PMID">23000402</idno>
		<ptr target="https://doi.org/10.1016/j.cmet.2012.09.002" />
	</analytic>
	<monogr>
		<title level="j">Cell Metabolism</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="414" to="419" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Abnormal metabolic processes involved in the pathogenesis of non-alcoholic fatty liver disease (Review)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Shao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Wu</surname></persName>
		</author>
		<idno type="DOI">10.3892/etm.2020.9154</idno>
		<idno type="PMID">32934691</idno>
		<ptr target="https://doi.org/10.3892/etm.2020.9154" />
	</analytic>
	<monogr>
		<title level="j">Experimental and Therapeutic Medicine</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page">26</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Humans possess two mitochondrial ferredoxins, Fdx1 and Fdx2, with distinct roles in steroidogenesis, heme, and Fe/S cluster biosynthesis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Sheftel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Stehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Pierik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>ElsÃ¤sser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>MÃ¼hlenhoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Webert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hobler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hannemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bernhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lill</surname></persName>
		</author>
		<idno type="DOI">10.1073/pnas.1004250107</idno>
		<idno type="PMID">20547883</idno>
		<ptr target="https://doi.org/10.1073/pnas.1004250107" />
	</analytic>
	<monogr>
		<title level="j">PNAS</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="11775" to="11780" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a</title>
		<author>
			<persName><forename type="first">H</forename><surname>Shimano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Horton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Hammer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Shimomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Goldstein</surname></persName>
		</author>
		<idno type="DOI">10.1172/JCI118951</idno>
		<idno type="PMID">8833906</idno>
		<ptr target="https://doi.org/10.1172/JCI118951" />
	</analytic>
	<monogr>
		<title level="j">The Journal of Clinical Investigation</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="1575" to="1584" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells</title>
		<author>
			<persName><forename type="first">H</forename><surname>Shimano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Horton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Shimomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Hammer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Goldstein</surname></persName>
		</author>
		<idno type="DOI">10.1172/JCI119248</idno>
		<idno type="PMID">9062341</idno>
		<ptr target="https://doi.org/10.1172/JCI119248" />
	</analytic>
	<monogr>
		<title level="j">The Journal of Clinical Investigation</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="846" to="854" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Metabolic effects of obesity: a review</title>
		<author>
			<persName><forename type="first">P</forename><surname>Singla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bardoloi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Parkash</surname></persName>
		</author>
		<idno type="DOI">10.4239/wjd.v1.i3.76</idno>
		<idno type="PMID">21537431</idno>
		<ptr target="https://doi.org/10.4239/wjd.v1.i3.76" />
	</analytic>
	<monogr>
		<title level="j">World Journal of Diabetes</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="76" to="88" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Greasing the wheels of the cancer machine: the role of lipid metabolism in cancer</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Snaebjornsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Janaki-Raman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schulze</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cmet.2019.11.010</idno>
		<idno type="PMID">31813823</idno>
		<ptr target="https://doi.org/10.1016/j.cmet.2019.11.010" />
	</analytic>
	<monogr>
		<title level="j">Cell Metabolism</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="62" to="76" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Mitochondrial metabolism promotes adaptation to proteotoxic stress</title>
		<author>
			<persName><forename type="first">P</forename><surname>Tsvetkov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Detappe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Keys</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Brune</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Ying</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Thiru</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Reidy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kugener</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rossen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kocak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kory</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tsherniak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Santagata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Whitesell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Ghobrial</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Markley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lindquist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Golub</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41589-019-0291-9</idno>
		<idno type="PMID">31133756</idno>
		<ptr target="https://doi.org/10.1038/s41589-019-0291-9" />
	</analytic>
	<monogr>
		<title level="j">Nature Chemical Biology</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="681" to="689" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Copper induces cell death by targeting lipoylated TCA cycle proteins</title>
		<author>
			<persName><forename type="first">P</forename><surname>Tsvetkov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Coy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Petrova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dreishpoon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Verma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Abdusamad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rossen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Joesch-Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Humeidi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Spangler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Eaton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Frenkel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kocak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Corsello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lutsenko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kanarek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Santagata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Golub</surname></persName>
		</author>
		<idno type="DOI">10.1126/science.abf0529</idno>
		<idno type="PMID">35298263</idno>
		<ptr target="https://doi.org/10.1126/science.abf0529" />
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="page" from="1254" to="1261" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">From the metabolic syndrome to NAFLD or vice versa?</title>
		<author>
			<persName><forename type="first">E</forename><surname>Vanni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bugianesi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kotronen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Minicis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yki-JÃ¤rvinen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Svegliati-Baroni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.dld.2010.01.016</idno>
		<idno type="PMID">20207596</idno>
		<ptr target="https://doi.org/10.1016/j.dld.2010.01.016" />
	</analytic>
	<monogr>
		<title level="j">Digestive and Liver Disease</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="320" to="330" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Deficiency in the lipid exporter abca1 impairs retrograde sterol movement and disrupts sterol sensing at the endoplasmic reticulum</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Yamauchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Iwamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Rogers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Abe-Dohmae</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fujimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ccy</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ishigami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kishimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kobayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ueda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Furukawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">Y</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yokoyama</surname></persName>
		</author>
		<idno type="DOI">10.1074/jbc.M115.662668</idno>
		<idno type="PMID">26198636</idno>
		<ptr target="https://doi.org/10.1074/jbc.M115.662668" />
	</analytic>
	<monogr>
		<title level="j">The Journal of Biological Chemistry</title>
		<imprint>
			<biblScope unit="volume">290</biblScope>
			<biblScope unit="page" from="23464" to="23477" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Ninjurin 1 has two opposing functions in tumorigenesis in a p53-dependent manner</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lucchesi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Scoumanne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1073/pnas.1711814114</idno>
		<idno type="PMID">29073078</idno>
		<ptr target="https://doi.org/10.1073/pnas.1711814114" />
	</analytic>
	<monogr>
		<title level="j">PNAS</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="page" from="11500" to="11505" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Ferredoxin reductase is critical for p53-dependent tumor suppression via iron regulatory protein 2</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yan</forename><forename type="middle">W</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lloyd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Duan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename></persName>
		</author>
		<idno type="DOI">10.1101/gad.299388.117</idno>
		<idno type="PMID">28747430</idno>
		<ptr target="https://doi.org/10.1101/gad.299388.117" />
	</analytic>
	<monogr>
		<title level="j">Genes &amp; Development</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="1243" to="1256" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Ferredoxin reductase and p53 are necessary for lipid homeostasis and tumor suppression through the ABCA1-SREBP pathway</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mohibi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Vasilatis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41388-021-02100-0</idno>
		<idno type="PMID">35121827</idno>
		<ptr target="https://doi.org/10.1038/s41388-021-02100-0" />
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="1718" to="1726" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
